10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Archives : Old artciles

Tuesday, October 4, 2011

Sharon Bio-Medicine Ltd:-Buy/sell/,growth prospects and recommendation,news and results,target price and analysis,view and outlook,multibagger

Scripscan:Sharon Bio-Medicine Ltd
BSE code:532908

Story:Sharon Bio-Medicine Ltd (SBML) is engaged in the manufacturing of Active Pharma Ingredients (API), Intermediates and Formulations (own brands). It has a diversified product portfolio with presence mainly in acute therapies such as anti-infectives and anti-biotics. SBML also has presence in chronic therapies such as diabetes and cardiovascular. In JY08 (financial year ends in June), it commenced its formulations business with manufacturing of its own brands targeting the domestic market. During JY10, the contribution of sales from formulations business to the total sales was 34.4%. SBML has four manufacturing facilities,three at Taloja in Maharashtra (two for manufacture of API and intermediates and one for Toxicology studies) and one at Dehradun in Uttaranchal for manufacturing of formulation products. During JY10, the Dehradun plant received UKMHRA certification. In addition, it has three R&D centers located at its manufacturing facilities. SBML has set up a R&D unit named sa- FORD (sanctuary for Research and Development Laboratories), which is a state-of-the-art animal testing and breeding facility atTaloja.SBML is committed to leverage the lucrative opportunities coming up by forward integrating into contract formulation research and manufacturing, entering high-margin, highly-sensitive oncology therapeutic segment, invested in new state-of-the-art API facilities targeting the regulated markets, expanding product pipelines by addressing the growing anti-depressant and antiretrovials therapeutic segments, filing DMFs for its key products, strengthening R&D capabilities, vigorously improving productivity in pursuit of operational excellence in all its activities and rank amongst the most efficient and effective companies in this sector. It has also received new approvals for its R&D facilities, which could reap benefits going ahead. This could help SBML to become a fully integrated company, emerge as a suitable partner for long-term relationships and cumulatively strengthen its potential to deliver substantial upside for all its stakeholders.Even though SBML is trading at a higher valuation than its peers we believe there is scope for further appreciation.The stock is currently trading at Rs.290 (~7.8x JY12 (E) EPS of Rs.37.7).A good hold at present prices.


No comments:

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner